Brooklyn Immunotherapeutics Inc (NYSEAMERICAN: BTX) incorporated an R&D center in Cambridge, Massachusetts, to focus on developing mRNA-based gene editing/ cellular-based remedies. The company obtained an exclusive global license from Novellus Therapeutics Limited and Factor Bioscience Limited to develop and commercialize cell-based remedies.
Develops advanced remedies
The company would use these therapies to cure rare blood disorders and cancer such as sickle cell disease.
Brooklyn’s CEO, Howard J. Federoff, said its new R&D center helps its research and development efforts. Co-locating with Novellus Therapeutics and Factor promotes its capability to collaborate and develop a variety of innovative and advanced therapeutics.
Novellus Therapeutics and Factor’s recent presentations at the ASGCT (American Society of Gene & Cell Therapy) conference strengthens its commitment to developing pathways to address real-world diseases for which no approved treatments exist in the market.
Federoff is thrilled to advance its R&D efforts to begin gene editing, cellular therapy transition, and commence its emerging clinical programs. Its primary impetus is on orphan diseases like sickle cell anemia, cell therapies to treat cancer, and familial amyloidosis.
Its recently licensed platform from Novellus Therapeutics and Factor comprises three innovative technologies that help the company utilize R&D at its new location.
Its first technology is the mRNA cell reprogramming technique. The company would apply mRNA-based GET (gene-editing technology) to analog and allogeneic cells.
Efficient mRNA delivery
A tunable nanolipid delivery system is its third technology to facilitate non-viral vector-based efficient delivery of its mRNA ex vivo. The company would also use this technology to efficiently deliver mRNA in vivo to eye, brain, skin, and lung tissues.
Raises $20 million
Brooklyn raised $20 million to expedite mRNA GET and cell therapies technology. It will use the funds for nanolipid particle platform and gene editing, cellular therapy transition for emerging clinical programs.
The recently licensed platform from Factor and Novellus Therapeutics plays an essential role in its corporate strategy. It helps the company to realize its vision of becoming a leader with several products in its pipeline.
Brooklyn gets access to a patented process for the development of mRNA-based gene editing compounds. It paves the way for introducing new treatments for several liquid indications and solid tumors, inherited disorders, and sickle cell anemia.
